BioTrove Shelves IPO Plans

Eight months after bucking the trend by filing to go public in a very unhospitable market, Woburn, MA-based BioTrove has evidently thought better of things. The MIT spinoff, which is developing tools for genomic analysis and drug discovery, today pulled the planned offering, which was to have been worth up to $75 million. BioTrove might undertake a private offiering, the company noted in its new filing with the SEC.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy